Your browser doesn't support javascript.
loading
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Yamaguchi, Kensei; Minashi, Keiko; Sakai, Daisuke; Nishina, Tomohiro; Omuro, Yasushi; Tsuda, Masahiro; Iwagami, Shiroh; Kawakami, Hisato; Esaki, Taito; Sugimoto, Naotoshi; Oshima, Takashi; Kato, Ken; Amagai, Kenji; Hosaka, Hisashi; Komine, Keigo; Yasui, Hisateru; Negoro, Yuji; Ishido, Kenji; Tsushima, Takahiro; Han, Shirong; Shiratori, Shinichi; Takami, Tomoko; Shitara, Kohei.
Afiliação
  • Yamaguchi K; Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer, Tokyo, Japan.
  • Minashi K; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
  • Sakai D; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
  • Nishina T; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Omuro Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Tsuda M; Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Iwagami S; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Sugimoto N; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Oshima T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Kato K; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Amagai K; Department of Gastroenterology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
  • Hosaka H; Department of Gastroenterology, Gunma Prefectural Cancer Center, Ota, Japan.
  • Komine K; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
  • Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Negoro Y; Department of Gastroenterology, Kochi Health Sciences Center, Kochi, Japan.
  • Ishido K; Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
  • Tsushima T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto, Japan.
  • Han S; Biostatistics and Research Decision Sciences, MSD K.K., Tokyo, Japan.
  • Shiratori S; Oncology Science Unit, MSD K.K., Tokyo, Japan.
  • Takami T; Oncology Science Unit, MSD K.K., Tokyo, Japan.
  • Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Cancer Sci ; 113(8): 2814-2827, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35701865
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Estomago Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Estomago Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão